Ƶ

Hot Human Brains; LATE Prevalence Revealed; Novel ALS Drug Wins Canadian Approval

— News and commentary from the world of neurology and neuroscience

Ƶ MedicalToday
Brain scan images with NeuroBreak in the center.

Healthy human and vary in temperature more than previously thought. (Brain)

Frequent were associated with an increased risk for incident Parkinson's disease, up to 5 years before diagnosis. (eClinical Medicine)

The investigational anti-tau antibody semorinemab of cerebral tau accumulation or clinical decline in prodromal to mild Alzheimer's disease. (JAMA Neurology)

Limbic-predominant age-related TDP-43 encephalopathy (LATE) neuropathologic change was seen in almost at autopsy and often co-existed with Alzheimer's neuropathology. (Acta Neuropathologica)

Software that lets people through an Apple Watch received FDA clearance, Rune Labs said.

Health Canada approved AMX0035 (Albrioza) -- a proprietary combination of sodium phenylbutyrate and taurursodiol -- for , Amylyx Pharmaceuticals announced. The FDA's decision is expected by September 29.

An automated, single-session pain management skills intervention up to 3 months in motivated orthopedic trauma surgery patients. (Anesthesia and Analgesia)

Spinal anesthesia was tied to higher use compared with general anesthesia in hip fracture patients, the REGAIN trial showed. (Annals of Internal Medicine)

Cardiometabolic multimorbidity was independently associated with the , regardless of genetic risk. (Lancet Healthy Longevity)

was not associated with increased risk of dementia and, surprisingly, was linked with a small decrease in risk. (Neurology)

Vutrisiran (Amvuttra), an injectable RNA interference drug to associated with hereditary transthyretin-mediated amyloidosis, won FDA approval, drugmaker Alnylam said.

  • Judy George covers neurology and neuroscience news for Ƶ, writing about brain aging, Alzheimer’s, dementia, MS, rare diseases, epilepsy, autism, headache, stroke, Parkinson’s, ALS, concussion, CTE, sleep, pain, and more.